McKesson said the combination will boost its ability meet the rising demand for affordable and high-quality cancer care -- "one of the most important segments in health care," according to the company.
The deal includes the purchase of all outstanding shares of U.S. Oncology for cash and the assumption of U.S. Oncology's outstanding debt.
The companies said they are trying to close the deal by the end of McKesson's third fiscal quarter on Dec. 31.McKesson said it expects the acquisition to be neutral to its per-share earnings in its current fiscal year and "modestly" accretive starting in the company's 2012 fiscal year. -- Written by Andrea Tse in New York.
>To contact the writer of this article, click here: Andrea Tse. >To follow the writer on Twitter, go to Andrea Tse. >To submit a news tip, send an email to: email@example.com.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts